Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Pathologic Residual Cancer Cells
Interventions: DRUG: Capecitabine, Oral, 500 Mg|DRUG: Vinorelbine Tartrate Oral
Sponsor: Zhiyong Yu